. 2019 Oct 19;92(1103):20190180. doi: 10.1259/bjr.20190180

Table 2. .

A summary of some of the primary targets in current PET imaging of cancer with potential for radiotherapy applications

Target pathway	Potential radiopharmaceuticals
Tumour hypoxia	¹⁸F-MISO ¹⁸F-FAZA ¹⁸F-HX4 ^60/61/62/64Cu-ATSM
Protein and cell membrane synthesis	¹¹C or ¹⁸F-choline ¹¹C-acetate
Transporter-targeted agents	¹¹C-MET ¹⁸F-FET ¹⁸F-FACBC
Receptor-targeted agents	⁶⁸Ga-DOTATOC/DOTANOC/DOTATATE ⁶⁸Ga-pentixafor
Protein-targeted agents	⁶⁸Ga-PSMA ¹⁸F-FLT

¹¹C-MET, ¹¹C-L-methyl-methionine; ^60/61/62/64Cu-ATSM, ^60/61/62/64copper(II)-diacetyl-bis(N⁴-methylthiosemicarbazone); ¹⁸F-FACBC, anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid; ¹⁸F-FAZA, ¹⁸F-fluoroazomycin; ¹⁸F-FET, ¹⁸F-fluoroethyltyrosine; ¹⁸F-FLT, ¹⁸F-fluorothymidine; ¹⁸F-HX4, ¹⁸F-flortanidazole; ¹⁸F-MISO, ¹⁸F-fluoromisonidazole;⁶⁸Ga-PSMA, ⁶⁸Ga-prostate-specific membrane antigen.